Disarming Staphylococcus aureus from destroying human cells by simultaneously neutralizing six cytotoxins with two human monoclonal antibodies

References

• Herrmann M, Smeltzer MS. Clinical significance in humans. In Staphylococcus: Genetics and Physiology. GA Somerville, editor. United Kingdom (UK): Caister Academic Press, FL23-44;2016.
   Google Scholar
• Tong SYC, Davis JS, Eichenberger E, Holland TL, Fowler VG. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin. Microbiol. Rev. 2015;28(3):603-61. doi:10.1128/CMR.00134-14
   PubMed Web of Science ®Google Scholar
• Spaan AN, Surewaard BG, Nijland R, van Strijp JA. Neutrophils versus Staphylococcus aureus: a biological tug of war. Annu. Rev. Microbiol. 2014;67:629-50. doi:10.1146/annurev-micro-092412-155746
   Web of Science ®Google Scholar
• Dryla A, Prustomersky S, Gelbmann D, Hanner M, Bettinger E, Kocsis B, Kustos T, Henics T, Meinke A, Nagy E. Comparison of antibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected patients. Clin. Diagn. Lab. Immunol. 2005;12(3):387-98.
   PubMedGoogle Scholar
• Pozzi C, Olaniyi R, Liljeroos L, Galgani I, Rappuoli R, Bagnoli F. Vaccines for Staphylococcus aureus and target populations. Curr Top Microbiol Immunol. 2016 Berlin, Heidelberg: Springer, 2016. doi: 10.1007/82_2016_54.
   Web of Science ®Google Scholar
• Fowler VG Jr., Proctor RA. Where does a Staphylococcus aureus vaccine stand? Clin. Microbiol. Infect. 2014;20(Suppl 5):66-75. doi:10.1111/1469-0691.12570
   PubMed Web of Science ®Google Scholar
• Alonzo F, Torres VJ. The bicomponent pore-forming leucocidins of Staphylococcus aureus. Microbiol Mol Biol Rev. 2014;78(2):199-230. doi:10.1128/MMBR.00055-13
   PubMed Web of Science ®Google Scholar
• Vandenesch F, Lina G, Henry T. Staphylococcus aureus hemolysins, bi-component leukocidins, and cytolytic peptides: a redundant arsenal of membrane-damaging virulence factors? Front. Cell. Infect. Microbiol. 2012;2:12.
   PubMed Web of Science ®Google Scholar
• Reyes-Robles T, Torres VJ. Staphylococcus aureus pore-forming toxins. Curr Top Microbiol Immunol. Berlin, Heidelberg: Springer, 2016. doi:10.1007/82_2016_16
   PubMed Web of Science ®Google Scholar
• Berube BJ, Bubeck Wardenburg J. Staphylococcus aureus alpha-toxin: nearly a century of intrigue. Toxins (Basel) 2013;5(6):1140-66. doi:10.3390/toxins5061140
   PubMed Web of Science ®Google Scholar
• Spaan AN, van Strijp JAG, Torres VJ. Leukocidins: staphylococcal bi-component pore-forming toxins find their receptors. Nat Rev Microbiol. 2017;15(7):435-447. doi:10.1038/nrmicro.2017.27
   PubMed Web of Science ®Google Scholar
• Anderson MJ, Anderson MJ, Lin YC, Gillman AN, Parks PJ, Schlievert PM, Peterson ML. Alpha-toxin promotes Staphylococcus aureus mucosal biofilm formation. Front Cell Infect Microbiol. 2012;2:64. doi:10.3389/fcimb.2012.00064.
   PubMed Web of Science ®Google Scholar
• Scherr TD, Hanke ML, Huang O, James DB, Horswill AR, Bayles KW, Fey PD, Torres VJ, Kielian T. Staphylococcus aureus biofilms induce macrophage dysfunction through Leukocidin AB and alpha-toxin. MBio. 2015;6(4):pii: e01021-15. doi:10.1128/mBio.01021-15
   Web of Science ®Google Scholar
• Alonzo F 3rd, Benson MA, Chen J, Novick RP, Shopsin B, Torres VJ. Staphylococcus aureus leucocidin ED contributes to systemic infection by targeting neutrophils and promoting bacterial growth in vivo. Mol Microbiol. 2012;83(2):423-35. doi:10.1111/j.1365-2958.2011.07942.x
   PubMed Web of Science ®Google Scholar
• Diep BA, Le VT, Visram ZC, Rouha H, Stulik L, Dip EC, Nagy G, Nagy E. Improved protection in a rabbit model of community-associated methicillin-resistant Staphylococcus aureus necrotizing pneumonia upon neutralization of leukocidins in addition to alpha-hemolysin. Antimicrob Agents Chemother. 2016;60(10):6333-40
   PubMed Web of Science ®Google Scholar
• Löffler B, Hussain M, Grundmeier M, Brück M, Holzinger D, Varga G, Roth J, Kahl BC, Proctor RA, Peters G. Staphylococcus aureus Panton-Valentine leukocidin is a very potent cytotoxic factor for human neutrophils. PLoS Pathog. 2010;6(1):e1000715. doi:10.1371/journal.ppat.1000715
   PubMed Web of Science ®Google Scholar
• Diep BA, Chan L, Tattevin P, Kajikawa O, Martin TR, Basuino L, Mai TT, Marbach H, Braughton KR, Whitney AR, et al. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Proc Natl Acad Sci USA. 2010;107(12):5587-92. doi:10.1073/pnas.0912403107
   PubMed Web of Science ®Google Scholar
• Malachowa N, Kobayashi SD, Braughton KR, Whitney AR, Parnell MJ, Gardner DJ, Deleo FR. Staphylococcus aureus leukotoxin GH promotes inflammation. J Infect Dis. 2012;206(8):1185-93. doi:10.1093/infdis/jis495
   PubMed Web of Science ®Google Scholar
• DuMont AL, Yoong P, Day CJ, Alonzo F 3rd, McDonald WH, Jennings MP, Torres VJ. Staphylococcus aureus LukAB cytotoxin kills human neutrophils by targeting the CD11b subunit of the integrin Mac-1. Proc Natl Acad Sci U S A. 2013;110(26):10794-9. doi:10.1073/pnas.1305121110
   PubMed Web of Science ®Google Scholar
• Reyes-Robles T, Alonzo F 3rd, Kozhaya L, Lacy DB, Unutmaz D, Torres VJ. Staphylococcus aureus leukotoxin ED targets the chemokine receptors CXCR1 and CXCR2 to kill leukocytes and promote infection. Cell Host Microbe. 2013;14(4):453-9. doi:10.1016/j.chom.2013.09.005
   PubMed Web of Science ®Google Scholar
• Alonzo F 3rd, Kozhaya L, Rawlings SA, Reyes-Robles T, DuMont AL, Myszka DG, Landau NR, Unutmaz D, Torres VJ. CCR5 is a receptor for Staphylococcus aureus leukotoxin ED. Nature 2013;493(7430):51-5.
   PubMed Web of Science ®Google Scholar
• Spaan AN, Henry T, van Rooijen WJ, Perret M, Badiou C, Aerts PC, Kemmink J, de Haas CJ, van Kessel KP, Vandenesch F, Lina G, van Strijp JA. The staphylococcal toxin Panton-Valentine leukocidin targets human C5a receptors. Cell Host Microbe. 2013;13(5):584-94. doi:10.1016/j.chom.2013.04.006.
   PubMed Web of Science ®Google Scholar
• Spaan AN, Vrieling M, Wallet P, Badiou C, Reyes-Robles T, Ohneck EA, Benito Y, de Haas CJ, Day CJ, Jennings MP, et al. The staphylococcal toxins γ-haemolysin AB and CB differentially target phagocytes by employing specific chemokine receptors. Nat Commun. 2014;5:5438. doi:10.1038/ncomms6438
   PubMed Web of Science ®Google Scholar
• Spaan AN, Reyes-Robles T, Badiou C, Cochet S, Boguslawski KM, Yoong P, Day CJ, de Haas CJ, van Kessel KP, Vandenesch F et al. Staphylococcus aureus targets the Duffy antigen receptor for chemokines (DARC) to lyse erythrocytes. Cell Host Microbe. 2015;18(3):363-70. doi:10.1016/j.chom.2015.08.001
   PubMed Web of Science ®Google Scholar
• Wilke GA, Bubeck Wardenburg J. Role of a disintegrin and metalloprotease 10 in Staphylococcus aureus alpha-hemolysin-mediated cellular injury. Proc Natl Acad Sci U S A. 2010;107(30):13473-8. doi:10.1073/pnas.1001815107
   PubMed Web of Science ®Google Scholar
• Gillet Y, Issartel B, Vanhems P, Fournet JC, Lina G, Bes M, Vandenesch F, Piémont Y, Brousse N, Floret D, Etienne J. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet. 2002;359(9308):753-9. doi:10.1016/S0140-6736(02)07877-7
   PubMed Web of Science ®Google Scholar
• del Giudice P, Blanc V, de Rougemont A, Bes M, Lina G, Hubiche T, Roudière L, Vandenesch F, Etienne J. Primary skin abscesses are mainly caused by Panton-Valentine leukocidin-positive Staphylococcus aureus strains. Dermatology. 2009;219(4):299-302. doi:10.1159/000232391
   PubMed Web of Science ®Google Scholar
• Stulik L, Malafa S, Hudcova J, Rouha H, Henics BZ, Craven DE, Sonnevend AM, Nagy E. Hemolysin activity of methicillin-susceptible S. aureus predicts ventilator-associated pneumonia. Am J Respir Crit Care Med. 2014;190(10):1139-48. doi:10.1164/rccm.201406-1012OC
   PubMed Web of Science ®Google Scholar
• Bubeck Wardenburg J, Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med. 2008;205(2):287-94. doi:10.1084/jem.20072208
   PubMed Web of Science ®Google Scholar
• Foletti D, Strop P, Shaughnessy L, Hasa-Moreno A, Casas MG, Russell M, Bee C, Wu S, Pham A, Zeng Z, et al. Mechanism of action and in vivo efficacy of a human-derived antibody against Staphylococcus aureus alpha-hemolysin. J Mol Biol. 2013;425(10):1641-54.
   PubMed Web of Science ®Google Scholar
• Hua L, Hilliard JJ, Shi Y, Tkaczyk C, Cheng LI, Yu X, Datta V, Ren S, Feng H, Zinsou R et al. Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia. Antimicrob Agents Chemother. 2014;58(2):1108-17. doi:10.1128/AAC.02190-13
   PubMed Web of Science ®Google Scholar
• Adhikari RP, Ajao AO, Aman MJ, Karauzum H, Sarwar J, Lydecker AD, Johnson JK, Nguyen C, Chen WH, Roghmann MC. Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections. J Infect Dis. 2012;206(6):915-23.
   PubMed Web of Science ®Google Scholar
• Fritz SA, Tiemann KM, Hogan PG, Epplin EK, Rodriguez M, Al-Zubeidi DN, Bubeck Wardenburg J, Hunstad DA. A serologic correlate of protective immunity against community-onset Staphylococcus aureus infection. Clin Infect Dis. 2013;56(11):1554-61. doi:10.1093/cid/cit123
   PubMed Web of Science ®Google Scholar
• Rasigade JP, Sicot N, Laurent F, Lina G, Vandenesch F, Etienne J. A history of Panton–Valentine leukocidin (PVL)-associated infection protects against death in PVL-associated pneumonia. Vaccine. 2011;29(25):4185-6. doi:10.1016/j.vaccine.2011.04.033
   PubMed Web of Science ®Google Scholar
• Rouha H, Badarau A, Visram ZC, Battles MB, Prinz B, Magyarics Z, Nagy G, Mirkina I, Stulik L, Zerbs M et al. Five birds, one stone: Neutralization of alpha-hemolysin and four bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody. MAbs. 2015;7(1):243-54. doi:10.4161/19420862.2014.985132
   PubMed Web of Science ®Google Scholar
• Diep BA, Hilliard JJ, Le VT, Tkaczyk C, Le HN, Tran VG, Rao RL, Dip EC, Pereira-Franchi EP, Cha P et al. Targeting alpha toxin to mitigate its lethal toxicity in ferret and rabbit models of Staphylococcus aureus necrotizing pneumonia. Antimicrob Agents Chemother. 2017;61(4):pii: e02456-16.
   Web of Science ®Google Scholar
• Badarau A, Rouha H, Malafa S, Battles MB, Walker L, Nielson N, Dolezilkova I, Teubenbacher A, Banerjee S, Maierhofer B et al. Context matters: The importance of dimerization-induced conformation of the LukGH leukocidin of Staphylococcus aureus for the generation of neutralizing antibodies. MAbs. 2016;8(7):1347-60. doi:10.1128/AAC.02456-16. doi:10.1080/19420862.2016.1215791
   PubMed Web of Science ®Google Scholar
• Janesch P, Rouha H, Weber S, Malafa S, Gross K, Maierhofer B, Badarau A, Visram ZC, Stulik L, Nagy E. Selective sensitization of human neutrophils to LukGH mediated cytotoxicity by Staphylococcus aureus and IL-8. J Infect. 2017;74(5):473-83.
   PubMed Web of Science ®Google Scholar
• Badarau A, Rouha H, Malafa S, Logan DT, Håkansson M, Stulik L, Dolezilkova I, Teubenbacher A, Gross K, Maierhofer B et al. Structure-function analysis of heterodimer formation, oligomerization and receptor binding of the Staphylococcus aureus bi-component toxin LukGH. J. Biol. Chem. 2015;290(1): 142-56. doi:10.1016/j.jinf.2017.02.004. doi:10.1074/jbc.M114.598110
   PubMed Web of Science ®Google Scholar
• Malachowa N, Whitney AR, Kobayashi SD, Sturdevant DE, Kennedy AD, Braughton KR, Shabb DW, Diep BA, Chambers HF, Otto M, DeLeo FR. Global changes in Staphylococcus aureus gene expression in human blood. PLoS One. 2011;6(4):e18617. doi:10.1371/journal.pone.0018617
   PubMed Web of Science ®Google Scholar
• DuMont AL, Yoong P, Surewaard BG, Benson MA, Nijland R, van Strijp JA, Torres VJ. Staphylococcus aureus elaborates the leukotoxin LukAB to mediate escape from within human neutrophils. Infect Immun. 2013;81(5):1830-41.
   PubMed Web of Science ®Google Scholar
• Chapman JR, Balasubramanian D, Tam K, Askenazi M, Copin R, Shopsin B, Torres VJ, Ueberheide BM. Using quantitative spectrometry to understand the influence of genetics and nutritional perturbations on the virulence potential of Staphylococcus aureus. Mol Cell Proteomics. 2017;16(4 suppl 1):S15-S28. doi:10.1074/mcp.O116.065581
   PubMed Web of Science ®Google Scholar
• Bischoff M, Romby P. Genetic regulation. In Staphylococcus: Genetics and Physiology. GA Somerville, editor. UK: Caister Academic Press, FL301-334;2016. doi:10.1128/IAI.00095-13
   Google Scholar
• Chua KY, Monk IR, Lin YH, Seemann T, Tuck KL, Porter JL, Stepnell J, Coombs GW, Davies JK, Stinear TP, Howden BP. Hyperexpression of α-hemolysin explains enhanced virulence of sequence type 93 community-associated methicillin-resistant Staphylococcus aureus. BMC Microbiol. 2014;14:31. doi:10.1186/1471-2180-14-31
   PubMed Web of Science ®Google Scholar
• Li T, He L, Song Y, Villaruz AE, Joo HS, Liu Q, Zhu Y, Wang Y, Qin J, Otto M, Li M. AraC-type regulator Rsp adapts Staphylococcus aureus gene expression to acute infection. Infect Immun. 2015;84(3):723-34. doi:10.1128/IAI.01088-15
   PubMed Web of Science ®Google Scholar
• Balasubramanian D, Ohneck EA, Chapman J, Weiss A, Kim MK, Reyes-Robles T, Zhong J, Shaw LN, Lun DS, Ueberheide B et al. Staphylococcus aureus coordinates leukocidin expression and pathogenesis by sensing metabolic fluxes via RpiRc. MBio. 2016;7(3):pii: e00818-16. doi:10.1128/mBio.00818-16
   Web of Science ®Google Scholar
• Ramundo MS, Beltrame CO, Botelho AM, Coelho LR, Silva-Carvalho MC, Ferreira-Carvalho BT, Nicolás MF, Guedes IA, Dardenne LE, O'Gara J, Figueiredo AM. A unique SaeS allele overrides cell-density dependent expression of saeR and lukSF-PV in the ST30-SCCmecIV lineage of CA-MRSA. Int J Med Microbiol. 2016;306(6):367-80.
   PubMed Web of Science ®Google Scholar
• Palazzolo-Ballance AM, Reniere ML, Braughton KR, Sturdevant DE, Otto M, Kreiswirth BN, Skaar EP, DeLeo FR. Neutrophil microbicides induce a pathogen survival response in community-associated methicillin-resistant Staphylococcus aureus. J Immunol. 2008;180(1):500-9. doi:10.1016/j.ijmm.2016.05.001. doi:10.4049/jimmunol.180.1.500
   PubMed Web of Science ®Google Scholar
• Loughman JA, Fritz SA, Storch GA, Hunstad DA. Virulence gene expression in human community-acquired Staphylococcus aureus infections. J Infect Dis. 2009;199(3):294-301. doi:10.1086/595982
   PubMed Web of Science ®Google Scholar
• Ishii K, Adachi T, Yasukawa J, Suzuki Y, Hamamoto H, Sekimizu K. Induction of virulence gene expression in Staphylococcus aureus by pulmonary surfactant. Infect Immun. 2014;82(4):1500-10. doi:10.1128/IAI.01635-13
   PubMed Web of Science ®Google Scholar
• Ventura CL, Malachowa N, Hammer CH, Nardone GA, Robinson MA, Kobayashi SD, DeLeo FR. Identification of a novel Staphylococcus aureus two-component leukotoxin using cell surface proteomics. PLoS One. 2010;5(7):e11634. doi:10.1371/journal.pone.0011634
   PubMed Web of Science ®Google Scholar
• Dumont AL, Nygaard TK, Watkins RL, Smith A, Kozhaya L, Kreiswirth BN, Shopsin B, Unutmaz D, Voyich JM, Torres VJ. Characterization of a new cytotoxin that contributes to Staphylococcus aureus pathogenesis. Mol Microbiol. 2011;79(3):814-25.
   PubMed Web of Science ®Google Scholar
• Thammavongsa V, Kim HK, Missiakas D, Schneewind O. Staphylococcal manipulation of host immune responses. Nat Rev Microbiol. 2015;13(9):529-43. doi:10.1038/nrmicro3521
   PubMed Web of Science ®Google Scholar
• Stulik L, Labrousse D, Croisier-Bertin D, Nagy G, Nagy E. Efficacy of ASN100, a combination of two human monoclonal antibodies neutralizing Staphylococcus aureus cytotoxins in a CA-MRSA rabbit necrotizing pneumonia model. Poster presentation at European Congress of Clinical Microbiology and Infectious Diseases; Apr 22–25, Vienna, Austria.
   Google Scholar
• Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis. 2007;195(2):202-11. doi:10.1086/510396
   PubMed Web of Science ®Google Scholar
• Verkaik NJ, Dauwalder O, Antri K, Boubekri I, de Vogel CP, Badiou C, Bes M, Vandenesch F, Tazir M, Hooijkaas H, et al. Immunogenicity of toxins during Staphylococcus aureus infection. Clin Infect Dis. 2010;50(1):61-8. doi:10.1086/648673
   PubMed Web of Science ®Google Scholar
• Thomsen IP, Dumont AL, James DB, Yoong P, Saville BR, Soper N, Torres VJ, Creech CB. Children with invasive Staphylococcus aureus disease exhibit a potently neutralizing antibody response to the cytotoxin LukAB. Infect Immun. 2014;82(3):1234-42. doi:10.1128/IAI.01558-13
   PubMed Web of Science ®Google Scholar
• Magyarics Z, Jilma B, Leslie F, Luperchio S, Nagy E, Stevens C. Safety and pharmacokinetics of ASN100, a monoclonal antibody combination for the prevention and treatment of Staphylococcus aureus infections, from a single ascending dose Phase 1 clinical study in healthy adult volunteers. Poster presentation at European Congress of Clinical Microbiology and Infectious Diseases; Apr 22–25, Vienna, Austria.
   Google Scholar
• Panton PN, Valentine FCO. Staphylococcal toxin. Lancet 1932;219(5665):506-8. doi:10.1016/S0140-6736(01)24468-7
   Google Scholar
• Olaniyi R, Pozzi C, Grimaldi L, Bagnoli F. Staphylococcus aureus-associated skin and soft tissue infections: Anatomical localization, epidemiology, therapy and potential prophylaxis. Curr Top Microbiol Immunol. Berlin, Heidelberg: Springer, 2016. doi: 10.1007/82_2016_32
   PubMed Web of Science ®Google Scholar
• Sause WE, Buckley PT, Strohl WR, Lynch AS, Torres VJ. Antibody-based biologics and their promise to combat Staphylococcus aureus infections. Trends Pharmacol Sci. 2016;37(3):231-41. doi:10.1016/j.tips.2015.11.008
   PubMed Web of Science ®Google Scholar